Attached files
| file | filename |
|---|---|
| 10-K - 10-K - CTI BIOPHARMA CORP | cti10k12312016document.htm |
| EX-32 - EXHIBIT 32 - CTI BIOPHARMA CORP | a2016exhibit32sect906certc.htm |
| EX-31.2 - EXHIBIT 31.2 - CTI BIOPHARMA CORP | a2016exhibit312sect302cert.htm |
| EX-31.1 - EXHIBIT 31.1 - CTI BIOPHARMA CORP | a2016exhibit311sect302cert.htm |
| EX-21.1 - EXHIBIT 21.1 - CTI BIOPHARMA CORP | a2016exhibit21110kfy2016su.htm |
| EX-12.1 - EXHIBIT 12.1 - CTI BIOPHARMA CORP | a2016exhibit121ratioofearn.htm |
Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in the Registration Statement of CTI BioPharma Corp. on Form S-3 (Nos. 333-108926, 333-134126, 333-149980, 333-149981, 333-152171, 333-157376, 333-160969, 333-163479, 333-161442, 333-177506, 333-182330, 333-183037, 333-192748, 333-192749, 333-200452 and 333-200453) and Form S-8 (Nos. 333-146624, 333-152168, 333-158260, 333-162955, 333-170044, 333-178158, 333-184004, 333-189611, 333-196510, 333-207176, 333-207177, 333-211006) of our report (which includes an explanatory paragraph as to the Company’s ability to continue as a going concern) dated March 2, 2017, with respect to our audits of the consolidated financial statements and the related consolidated financial statement schedule of CTI BioPharma Corp. as of December 31, 2016 and 2015 and for the years ended December 31, 2016, 2015 and 2014 and our report dated March 2, 2017 with respect to our audit of the effectiveness of internal control over financial reporting of CTI BioPharma Corp. as of December 31, 2016, which reports are included in this Annual Report on Form 10-K of CTI BioPharma Corp. for the year ended December 31, 2016.
/s/ Marcum LLP
Marcum LLP
San Francisco, CA
March 2, 2017